Array comparative genomic hybridization reveals frequent alterations of G1/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone

Genes Chromosomes and Cancer

Volumn 50, Issue 5, 2011, Pages 291-306

  Niini, Tarja ^a   Lahti, Leo ^a,b   Michelacci, Francesca ^c   Ninomiya, Shinsuke ^a   Hattinger, Claudia Maria ^c   Guled, Mohamed ^a   Böhling, Tom ^a   Picci, Piero ^c   Serra, Massimo ^c   Knuutila, Sakari ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b AALTO UNIVERSITY   (Finland)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; STEM CELL FACTOR; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CDKN2A GENE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHROMOSOME 10; CHROMOSOME 12P; CHROMOSOME 13Q; CHROMOSOME 14Q; CHROMOSOME 17Q; CHROMOSOME 18Q; CHROMOSOME 19P; CHROMOSOME 20Q; CHROMOSOME 22Q; CHROMOSOME 4Q; CHROMOSOME 5P; CHROMOSOME 6P; CHROMOSOME 7P; CHROMOSOME 8P; CHROMOSOME 8Q; CHROMOSOME 9P; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA HYBRIDIZATION; DNA ISOLATION; DNA METHYLATION; FEMALE; GENE; GENETIC SCREENING; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ING1 GENE; KDR GENE; KIT GENE; MALE; MDM2 GENE; MICROARRAY ANALYSIS; ONCOGENE MYC; OSTEOSARCOMA; P14 ARF GENE; P16 INK4A GENE; PDGFRA GENE; PRIORITY JOURNAL; RARE DISEASE; RB1 GENE; TP53 GENE; UNDIFFERENTIATED PLEOMORPHIC SARCOMA OF THE BONE;

ADULT; AGED; BONE NEOPLASMS; CHILD; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; FEMALE; FIBROSARCOMA; G1 PHASE; GENES, P16; GENES, P53; GENES, RETINOBLASTOMA; HUMANS; MALE; MIDDLE AGED; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; S PHASE; SURVIVAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; YOUNG ADULT;

EID: 79952448160     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20851     Document Type: Article

References (57)

1. Atiye J, Wolf M, Kaur S, Monni O, Bohling T, Kivioja A, Tas E, Serra M, Tarkkanen M, Knuutila S. 2005. Gene amplifications in osteosarcoma-CGH microarray analysis. Genes Chromosomes Cancer 42: 158-163.
2. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel CH, Getz G, Antipin Y, Beroukhim R, Major JE, Hatton C, Nicoletti R, Hanna M, Sharpe T, Fennell TJ, Cibulskis K, Onofrio RC, Saito T, Shukla N, Lau C, Nelander S, Silver SJ, Sougnez C, Viale A, Winckler W, Maki RG, Garraway LA, Lash A, Greulich H, Root DE, Sellers WR, Schwartz GK, Antonescu CR, Lander ES, Varmus HE, Ladanyi M, Sander C, Meyerson M, Singer S. 2010. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 42: 715-721.
3. Benassi MS, Molendini L, Gamberi G, Magagnoli G, Ragazzini P, Gobbi GA, Sangiorgi L, Pazzaglia L, Asp J, Brantsing C, Picci P. 2001. Involvement of INK4A gene products in the pathogenesis and development of human osteosarcoma. Cancer 92: 3062-3067.
4. Bozzi F, Tamborini E, Negri T, Pastore E, Ferrari A, Luksch R, Casanova M, Pierotti MA, Bellani FF, Pilotti S. 2007. Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors. Cancer 109: 1638-1645.
5. Broders AC, Hargrave R, Meyerding HW. 1939. Pathological features of soft tissue fibrosarcoma. With special reference to the grade of its malignancy. Surg Gynecol Obstet 69: 267-280.
6. Burger H, den Bakker MA, Kros JM, van Tol H, de Bruin AM, Oosterhuis W, van den Ingh HF, van der Harst E, de Schipper HP, Wiemer EA, Nooter K. 2005. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther 4: 1270-1274.
7. Campos EI, Chin MY, Kuo WH, Li G. 2004. Biological functions of the ING family tumor suppressors. Cell Mol Life Sci 61: 2597-2613.
8. Chibon F, Lagarde P, Salas S, Perot G, Brouste V, Tirode F, Lucchesi C, de Reynies A, Kauffmann A, Bui B, Terrier P, Bonvalot S, Le Cesne A, Vince-Ranchere D, Blay JY, Collin F, Guillou L, Leroux A, Coindre JM, Aurias A. 2010. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 16: 781-787.
9. Cox DR. 1972. Regression models and life tables (with discussion). J Royal Stat Soc B 34: 187-220.
10. DuBois S, Demetri G. 2007. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 109: 813-819.
11. Efron B. 1977. The efficiency of Cox's likelihood function for censored data. J Am Stat Assoc 72: 557-565.
12. Entz-Werle N, Marcellin L, Gaub MP, Guerin E, Schneider A, Berard-Marec P, Kalifa C, Brugiere L, Pacquement H, Schmitt C, Tabone MD, Jeanne-Pasquier C, Terrier P, Dijoud F, Oudet P, Lutz P, Babin-Boilletot A. 2005. Prognostic significance of allelic imbalance at the c-kit gene locus and c-kit overexpression by immunohistochemistry in pediatric osteosarcomas. J Clin Oncol 23: 2248-2255.
13. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, Herman JG. 2000. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 60: 129-133.
14. Fletcher CDM, Unni KK, Mertens F. 2002. World Health Organization Classification of Tumours, Pathology, and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARCPress, 427 p.
15. Fuchs B, Inwards CY, Janknecht R. 2004. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin Cancer Res 10: 1344-1353.
16. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. 2004. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 5: R80.
17. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. 1996. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826.
18. Honoki K, Stojanovski E, McEvoy M, Fujii H, Tsujiuchi T, Kido A, Takakura Y, Attia J. 2007. Prognostic significance of p16 INK4a alteration for Ewing sarcoma: A meta-analysis. Cancer 110: 1351-1360.
19. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, Wexler LH, Gorlick R, Meyers P, Ladanyi M. 2005. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: A highly lethal subset associated with poor chemoresponse. J Clin Oncol 23: 548-558.
20. Kawaguchi K, Oda Y, Sakamoto A, Saito T, Tamiya S, Iwamoto Y, Tsuneyoshi M. 2002. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years. Mod Pathol 15: 878-888.
21. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F, Ishii S. 2000. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6: 572-577.
22. Kresse SH, Ohnstad HO, Paulsen EB, Bjerkehagen B, Szuhai K, Serra M, Schaefer KL, Myklebost O, Meza-Zepeda LA. 2009. LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization. Genes Chromosomes Cancer 48: 679-693.
23. Ladanyi M, Gorlick R. 2000. Molecular pathology and molecular pharmacology of osteosarcoma. Pediatr Pathol Mol Med 19: 391-413.
24. Larramendy ML, Tarkkanen M, Blomqvist C, Virolainen M, Wiklund T, Asko-Seljavaara S, Elomaa I, Knuutila S. 1997. Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker. Am J Pathol 151: 1153-1161.
25. Lau CC, Harris CP, Lu XY, Perlaky L, Gogineni S, Chintagumpala M, Hicks J, Johnson ME, Davino NA, Huvos AG, Meyers PA, Healy JH, Gorlick R, Rao PH. 2004. Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer 39: 11-21.
26. Lee YH, Tokunaga T, Oshika Y, Suto R, Yanagisawa K, Tomisawa M, Fukuda H, Nakano H, Abe S, Tateishi A, Kijima H, Yamazaki H, Tamaoki N, Ueyama Y, Nakamura M. 1999. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 35: 1089-1093.
27. Lopez-Guerrero JA, Pellin A, Noguera R, Carda C, Llombart-Bosch A. 2001. Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lab Invest 81: 803-814.
28. Lopez-Guerrero JA, Lopez-Gines C, Pellin A, Carda C, Llombart-Bosch A. 2004. Deregulation of the G1 to S-phase cell cycle checkpoint is involved in the pathogenesis of human osteosarcoma. Diagn Mol Pathol 13: 81-91.
29. Mairal A, Terrier P, Chibon F, Sastre X, Lecesne A, Aurias A. 1999. Loss of chromosome 13 is the most frequent genomic imbalance in malignant fibrous histiocytomas. A comparative genomic hybridization analysis of a series of 30 cases. Cancer Genet Cytogenet 111: 134-138.
30. Maitra A, Roberts H, Weinberg AG, Geradts J. 2001. Loss of p16(INK4a) expression correlates with decreased survival in pediatric osteosarcomas. Int J Cancer 95: 34-38.
31. Man TK, Lu XY, Jaeweon K, Perlaky L, Harris CP, Shah S, Ladanyi M, Gorlick R, Lau CC, Rao PH. 2004. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 4: 45.
32. Martignetti JA, Desnick RJ, Aliprandis E, Norton KI, Hardcastle P, Nade S, Gelb BD. 1999. Diaphyseal medullary stenosis with malignant fibrous histiocytoma: A hereditary bone dysplasia/cancer syndrome maps to 9p21-22. Am J Hum Genet 64: 801-807.
33. Martignetti JA, Gelb BD, Pierce H, Picci P, Desnick RJ. 2000. Malignant fibrous histiocytoma: Inherited and sporadic forms have loss of heterozygosity at chromosome bands 9p21-22-evidence for a common genetic defect. Genes Chromosomes Cancer 27: 191-195.
34. McIntyre A, Summersgill B, Grygalewicz B, Gillis AJ, Stoop J, van Gurp RJ, Dennis N, Fisher C, Huddart R, Cooper C, Clark J, Oosterhuis JW, Looijenga LH, Shipley J. 2005. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res 65: 8085-8089.
35. Mejia-Guerrero S, Quejada M, Gokgoz N, Gill M, Parkes RK, Wunder JS, Andrulis IL. 2010. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma. Genes Chromosomes Cancer 49: 518-525.
36. Miller CW, Aslo A, Campbell MJ, Kawamata N, Lampkin BC, Koeffler HP. 1996. Alterations of the p15, p16, and p18 genes in osteosarcoma. Cancer Genet Cytogenet 86: 136-142.
37. Nielsen GP, Burns KL, Rosenberg AE, Louis DN. 1998. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. Am J Pathol 153: 159-163.
38. Niini T, Lopez-Guerrero JA, Ninomiya S, Guled M, Hattinger CM, Michelacci F, Bohling T, Llombart-Bosch A, Picci P, Serra M, Knuutila S. 2010. Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone-An array comparative genomic hybridization study. Genes Chromosomes Cancer 49: 132-143.
39. Oh JH, Kim HS, Kim HH, Kim WH, Lee SH. 2006. Aberrant methylation of p14ARF gene correlates with poor survival in osteosarcoma. Clin Orthop Relat Res 442: 216-222.
40. Patino-Garcia A, Sierrasesumaga L. 1997. Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients. Cancer Genet Cytogenet 98: 50-55.
41. Patino-Garcia A, Pineiro ES, Diez MZ, Iturriagagoitia LG, Klussmann FA, Ariznabarreta LS. 2003. Genetic and epigenetic alterations of the cell cycle regulators and tumor suppressor genes in pediatric osteosarcomas. J Pediatr Hematol Oncol 25: 362-367.
42. Ragland BD, Bell WC, Lopez RR, Siegal GP. 2002. Cytogenetics and molecular biology of osteosarcoma. Lab Invest 82: 365-373.
43. Simons A, Schepens M, Jeuken J, Sprenger S, van de Zande G, Bjerkehagen B, Forus A, Weibolt V, Molenaar I, van den Berg E, Myklebost O, Bridge J, van Kessel AG, Suijkerbuijk R. 2000. Frequent loss of 9p21 (p16(INK4A)) and other genomic imbalances in human malignant fibrous histiocytoma. Cancer Genet Cytogenet 118: 89-98.
44. Squire JA, Pei J, Marrano P, Beheshti B, Bayani J, Lim G, Moldovan L, Zielenska M. 2003. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer 38: 215-225.
45. Steiner GC, Jundt G, Martignetti JA. 2002. Malignant fibrous histiocytoma of bone. In: Fletcher CDM, Unni KK and Mertens F, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARCPress, p 294.
46. Sulzbacher I, Birner P, Trieb K, Traxler M, Lang S, Chott A. 2003. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol 16: 66-71.
47. Tamborini E, Bonadiman L, Negri T, Greco A, Staurengo S, Bidoli P, Pastorino U, Pierotti MA, Pilotti S. 2004. Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer. Clin Cancer Res 10: 8214-8219.
48. Tarkkanen M, Larramendy ML, Bohling T, Serra M, Hattinger CM, Kivioja A, Elomaa I, Picci P, Knuutila S. 2006. Malignant fibrous histiocytoma of bone: Analysis of genomic imbalances by comparative genomic hybridisation and C-MYC expression by immunohistochemistry. Eur J Cancer 42: 1172-1180.
49. Taubert H, Berger D, Hinze R, Meye A, Wurl P, Hogendoorn PC, Holzhausen HJ, Schmidt H, Rath FW. 1998. How is the mutational status for tumor suppressors p53 and p16(INK4A) in MFH of the bone? Cancer Lett 123: 147-151.
50. Tibshirani R, Hastie T, Narasimhan B, Chu G. 2002. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 99: 6567-6572.
51. Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y. 2000. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet 120: 91-98.
52. Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y, Yamamuro T. 1994. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 54: 3042-3048.
53. Wei G, Lonardo F, Ueda T, Kim T, Huvos AG, Healey JH, Ladanyi M. 1999. CDK4 gene amplification in osteosarcoma: Reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int J Cancer 80: 199-204.
54. Wei G, Antonescu CR, de Alava E, Leung D, Huvos AG, Meyers PA, Healey JH, Ladanyi M. 2000. Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer 89: 793-799.
55. Weng WH, Ahlen J, Lui WO, Brosjo O, Pang ST, Von Rosen A, Auer G, Larsson O, Larsson C. 2003. Gain of 17q in malignant fibrous histiocytoma is associated with a longer disease-free survival and a low risk of developing distant metastasis. Br J Cancer 89: 720-726.
56. Ythier D, Larrieu D, Brambilla C, Brambilla E, Pedeux R. 2008. The new tumor suppressor genes ING: Genomic structure and status in cancer. Int J Cancer 123: 1483-1490.
57. Zhu Z, Luo Z, Li Y, Ni C, Li H, Zhu M. 2009. Human inhibitor of growth 1 inhibits hepatoma cell growth and influences p53 stability in a variant-dependent manner. Hepatology 49: 504-512.